eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Thornton & Ross Ltd

Telephone: +44 (0)1484 842217
Fax: +44 (0)1484 847301
WWW: http://www.thorntonandross.com
Medical Information Direct Line: +44(0)1484 848 251
Medical Information e-mail: phv@thorntonross.co.uk
Customer Care direct line: +44(0)1484 842 217
Medical Information Fax: +44(0)1484 847 301

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 21/11/2011
SPC Galpseud Plus Linctus


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Galpseud Plus Linctus OR Vantage Galpseud Plus Linctus


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active Ingredients:

Per 5ml Dose:

Pseudoephedrine hydrochloride BP

30mg

Chlorphenamine maleate BP

2.0mg

For excipients, see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Oral liquid.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the relief of allergic rhinitis.


Go to top of the page
4.2 Posology and method of administration

For oral administration.

Adults:

Two 5ml spoonfuls three times daily.

Children:

Under 2 years: Not recommended.

2 – 6 years: 2.5ml three times daily.

6 – 12 years: 5ml three times daily.

Not more than 3 doses should be given in any 24 hours


Go to top of the page
4.3 Contraindications

Contra-indicated in patients with a known hypersensitivity to pseudoephedrine hydrochloride or chlorphenamine maleate or any of the other ingredients. Contra-indicated in epileptics because of the antihistamine content and in patients currently taking or within 2 weeks of stopping monoamine oxidase inhibitors. Contra-indicated in hypertension or in patients receiving antihypertensive therapy.

Not recommended for children under 2 years.


Go to top of the page
4.4 Special warnings and precautions for use

Asthmatics should consult a medical practitioner before using this product. Caution should be exercised in patients with renal impairment, urinary retention, diabetes, hyperthyroidism, glaucoma, hepatic impairment or cardiovascular disease and those taking other sympathomimetic agents, such as decongestants, amphetamine-like psychostimulants and appetite suppressants. The effects of single dose of Galpseud Plus/Vantage Galpseud Plus on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment. As with other sympathomimetic agents, caution should be exercised in patients with prostatic enlargement or bladder dysfunction.

In severe hepatic or renal dysfunction, a single dose of Galpseud Plus/Vantage Galpsud Plus should be given, and the patient's response used as a guide to the dosage requirement for further administration.

If symptoms persist consult your doctor.

Do not exceed the stated dose.

Do not take with other cough and cold medicine.

Consult a pharmacist or other healthcare professional before use in children under 6 years.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The antibacterial agent furazolidone is known to cause progressive inhibition of monoamine oxidase and although there are no reports of a hypertentive crisis having occurred, it should not be administered concurrently with Galpseud Plus/Vantage Galpseud Plus.

There may be an increased risk of arrythmias if pseudoephedrine is given to patients receiving cardiac glycosides or tricyclic antidepressants. Pseudoephedrine may reduce the hypotensive effect of antihypertensives with sympathomimetic activity. Concurrent use of pseudoephedrine with monoamine oxidase inhibitors may cause a hypertensive crisis. Chlorphenamine may enhance the sedative effects of CNS depressants, including alcohol, barbiturates, hypnotics, anxiolytics, sedatives and anti-psychotics. As chlorphenamine possesses anticholinergic activity the effects of some anticholinergics may be potentiated.


Go to top of the page
4.6 Pregnancy and lactation

Not to be used during pregnancy and lactation without prior consultant with a medical practitioner. Pseudoephedrine is excreted in breast milk in small amounts.


Go to top of the page
4.7 Effects on ability to drive and use machines

May cause drowsiness, if affected do not drive or operate machinery. The drowsiness may be potentiated by alcohol or other central sedatives.


Go to top of the page
4.8 Undesirable effects

Pseudoephedrine may cause anxiety, tremor, cardiac arrhythmias, palpitations, tachycardia, hypertension, nausea, vomiting, headache and may occasionally cause insomnia and urinary retention in men. Rarely sleep disturbance and hallucinations have been reported.

There have been rare cases of psychosis following misuse of pseudoephedrine.

Chlorphenamine may cause drowsiness, nausea, vomiting, headaches, blurred vision, anorexia and dryness of the mouth.

The administration of antihistamines has also been associated with rash, angioedema, convulsions, parasthesias, dizziness and constipation.


Go to top of the page
4.9 Overdose

Symptoms of overdose may include restlessness, drowsiness, tetany, hallucinations, excitement, ataxia, convulsions, fever, nausea, vomiting, difficulty in micturition, flushing, palpitations, tachycardia, cardiac arrhythmias and respiratory difficulties. Overdose should be treated by general symptomatic and supportive means. In the event of gross overdose the stomach may be emptied by airways protective gastric lavage. If consciousness is impaired or if respiration or circulatory difficulties are evident, appropriate supportive measures should be taken to maintain a patient's airway and to stabilise cardiovascular function. Convulsions should be controlled by immediate appropriate measures.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pseudoephedrine has direct and indirect sympathomimetic activity and is an orally effective upper respiratory tract decongestant.

Pseudoephedrine is substantially less potent than ephedrine in producing both tachycardia and elevation in systolic blood pressure and considerably less potent in causing stimulation of the central nervous system.

Chlorphenamine is one of the most potent anti-histamines. It is useful in the control of symptoms which are allergic in origin. It helps to provide relief from nasal stuffiness and watering of the eyes.


Go to top of the page
5.2 Pharmacokinetic properties

Pseudoephedrine hydrochloride is readily and completely absorbed from the gastro-intestinal tract. It is resistant to metabolism by monoamine oxidase and is largely excreted unchanged in the urine.

Chlorphenamine maleate is readily absorbed from the gastro-intestinal tract. It is extensively metabolised in the liver and excreted in the urine.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Citric acid monohydrate BP (E330)

Sodium hydroxybenzoates (E215, E217, E219)

Ethanol 96% BP

Amaranth (E123)

Carmellose sodium BP (E466)

Saccharin sodium BP

Menthol BP

Condensed milk flavour (F12516)

Orange flavour (17.40.7040)

Glycerol BP (E422)

Purified Water Ph.Eur.


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

Two years from the date of manufacture.


Go to top of the page
6.4 Special precautions for storage

Protect from light.

Store below 25°C.


Go to top of the page
6.5 Nature and contents of container

Amber HDPE 2 litre Winchester with a polypropylene cap.

Amber glass bottle with a 28mm tamper evident child resistant closure with a low density polyethylene plug

Pack size: 150, 200, 300 and 500ml.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Thornton & Ross Ltd.

Linthwaite

Huddersfield

HD7 5QH

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00240/0108


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

8 July 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

12th Feb 2010


Go to top of the page
11 DOSIMETRY

Not Applicable


Go to top of the page
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Not Applicable



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/25332/SPC/


Active Ingredients/Generics

 
   chlorphenamine maleate
   pseudoephedrine hydrochloride